Despite early death concerns, FDA advisers back J&J and Legend's Carvykti and BMS' Abecma for earlier myeloma

Even though the BCMA CAR-T therapies Carvykti and Abecma showed a potential problem of early patient deaths in their separate trials, experts on the FDA’s Oncologic Drugs Advisory Committee (ODAC) still believe that the drugs’ long-term benefits outweigh their risks.